[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-transplant-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-transplant-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,77,100,140,167,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632851","effect-of-preoperative-oral-carbohydrate-loading-on-postoperative-outcomes-in-liver-transplant-patients-100632851",false,"NCT07519057","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients","Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients: A Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* age ≥ 18 years\n* elective liver transplantation at the Department of General, Transplant, and Liver Surgery, Medical University of Warsaw\n* grafts from brain-dead donors\n* MELD score \\\u003C35\n\nExclusion Criteria:\n\n* acute liver failure\n* insulin-dependent diabetes mellitus\n* gastroparesis\n* mechanical bowel obstruction\n* liver retransplantation within less than 6 months of the primary transplant","ALL","18 Years",{"count":19,"type":20},434,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of the study is to evaluate the effect of preoperative oral carbohydrate loading on postoperative outcomes in liver transplant recipients. The results of this study may contribute to improving recovery after liver transplantation and shortening postoperative hospital stay in these patients.\n\nParticipants will be randomly assigned to either the study group or the control group. Patients assigned to the study group will receive 400 mL of a carbohydrate beverage (Nutricia preOp®), to be consumed up to 2 hours before the anesthesia induction. Patients assigned to the control group will receive 400 mL of a placebo administered in an identical manner as in the study group. Participants will not be informed which group they have been assigned to.\n\nIn the postoperative period, routine laboratory and imaging tests will be performed, and their results will be used to assess the effects of the intervention. Follow-up of the patient's clinical course is planned for up to 30 days after surgery. The schedule of follow-up visits will not differ from standard clinical practice.",[26,27,28,29],"Liver Transplantation","Liver Transplant","Liver Transplant Surgery","End Stage Liver Disease",[31,32,33,26,27,34,35],"Preoperative Oral Carbohydrate Loading","POCL","Nutricia PreOp","Carbohydrate drink","Preoperative Carbohydrate Loading","RECRUITING","2026-06-01",{"date":39,"type":40},"2026-06-03","ACTUAL",{"date":42,"type":40},"2026-05-27",{"date":44,"type":20},"2028-08",{"name":46,"class":47},"Medical University of Warsaw","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100637848","evaluate-the-performance-of-the-dexcom-g7-continuous-glucose-monitoring-cgm-system-in-critically-ill-patients-undergoing-major-abdominal-surgery-and-solid-organ-transplantation-which-require-blood-glucose-monitoring-for-intensive-insulin-therapy-100637848","NCT07611721","Evaluate the Performance of the Dexcom G7 Continuous Glucose Monitoring (CGM) System in Critically Ill Patients Undergoing Major Abdominal Surgery and Solid Organ Transplantation Which Require Blood Glucose Monitoring for Intensive Insulin Therapy.","Determining the Reliability and Accuracy of the Dexcom G7 Continuous Glucose Monitoring System in the ICU","DREAM-ICU","Inclusion Criteria:\n\n* Age 18 years or over\n* Intensive care unit admission\n* Requiring blood glucose monitoring for insulin therapy\n\nExclusion Criteria:\n\n* High-dose ascorbic acid or acetaminophen \\> 4g\u002Fday\n* Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician",{"count":58,"type":20},62,[23],"Main objective:\n\nThe goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.\n\nOn admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.\n\nSensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.\n\nSensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.\n\nPatients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.\n\nCalibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.\n\nCalibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol\u002FL).\n\nCalibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol\u002FL) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol\u002FL).\n\nHypothesis:\n\n* Ho: No difference in mean absolute relative difference (MARD) between calibrated and non-calibrated sensors.\n* Ha: Calibrated sensors have lower mean absolute relative difference (δ = 4%, SD = 5%).\n\nFurther objectives:\n\nTo evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.\n\nTo identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.",[62,63,28,64,65,66],"CGM","Intensive Care (ICU)","Solid Organ Transplantation","Major Abdominal Surgeries","Diabetes (Insulin-requiring, Type 1 or Type 2)","2026-05-20",{"date":69,"type":40},"2026-05-28",{"date":71,"type":40},"2026-01-14",{"date":73,"type":20},"2027-04",{"name":75,"class":76},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100586511","open-label-trial-of-deceased-donor-livers-transplanted-after-dhope-with-exvivo-liver-perfusion-100586511","NCT06916325","Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion","DeLIVER Trial: A Prospective, Multi-Center, Single-Arm, Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion","Participant Inclusion Criteria:\n\n1. Participant is able to provide informed consent and HIPAA authorization\n2. Age ≥18 years\n3. Participant is registered as an active first-time liver transplant candidate on the United Network for Organ Sharing (UNOS) waiting list for primary liver transplantation\n\n   \\- For participants with hepatocellular carcinoma (HCC) as indication for Orthotopic Liver Transplantation, the tumor must be within Milan Criteria or down-staged to Milan Criteria at the time of transplant\n4. Participant is willing to comply with the study requirements and procedures\n\nParticipant Exclusion Criteria:\n\n1. Participant will undergo concurrent multi-organ transplantations (liver-kidney, liver-lung, etc.)\n2. Participant is listed for liver transplantation due to fulminant liver failure (UNOS status 1A)\n3. Participant is listed for a repeat liver transplantation (\\>1 graft)\n4. Participant is pregnant\n5. Participant is on respiratory (ventilator dependent) and\u002For cardiocirculatory support (defined as mechanical circulatory support which requires at least one intravenous inotrope to maintain hemodynamics)\n6. Participant is enrolled in an interventional clinical trial with an investigational drug or device\n7. Presence of other medical, social, or psychological conditions that in the investigator's opinion, could limit the participant's ability to participate in the clinical trial",{"count":85,"type":20},215,[23],"The purpose of this clinical study is to confirm the safety and effectiveness of dual hypothermic oxygenated perfusion (DHOPE) using the Liver Assist to preserve deceased donor livers for transplantation.",[28,26],"NOT_YET_RECRUITING","2026-04-16",{"date":92,"type":40},"2026-04-21",{"date":94,"type":20},"2027-01",{"date":96,"type":20},"2033-04",{"name":98,"class":99},"XVIVO Perfusion","INDUSTRY",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100508347","online-prehabilitation-for-patients-awaiting-liver-transplantation-100508347","NCT05899231","Online Prehabilitation for Patients Awaiting Liver Transplantation","OPAL: Online Prehabilitation for Patients Awaiting Liver Transplantation - a Multicenter Randomized Controlled Trial to Reduce Physical Frailty and Improve Health Outcomes","OPAL","Inclusion Criteria:\n\n≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.\n\nExclusion Criteria:\n\n* Listed for living related donor transplantation with expected time on the wait list \\\u003C12 weeks, or model for end-stage liver disease (MELD-Na) Score \\>26 (Justification: time to transplant is very short)\n* Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)\n* Unable to provide informed consent\n* Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation\n* Life expectancy less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)\n* Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure\n* Transplant indication is cholangiocarcinoma.",{"count":109,"type":20},177,[23],"Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.\n\nThe proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.\n\nThe primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.",[113,28,114],"Cirrhosis, Liver","Liver Disease",[116,117,118,119,120,121,122,123,124,125,126,127,128,129],"frailty","transplant","nutrition","exercise","ehealth","application","wellness","prehabilitation","sarcopenia","malnutrition","physical function","digital","virtual","online","2026-04-07",{"date":132,"type":40},"2026-04-08",{"date":134,"type":40},"2023-07-12",{"date":136,"type":20},"2026-09",{"name":138,"class":47},"University of Alberta",6,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100569738","colorectal-metastasis-to-liver-extraction-with-auxiliary-transplant-and-delayed-resection-100569738","NCT06698146","Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection","Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection Registry Study","CLEAR","Inclusion:\n\n1. All Patients of either gender ≥ 18 years of age who are listed for Liver transplant candidates at Northwestern with liver metastases due to colorectal cancer (CRLM).\n2. Subjects must be able to provide informed consent themselves and without the use of a legally authorized representative (LAR), to be determined by the PI or Sub-I at the time of Consent.\n\nExclusion:\n\n1. Adults unable to consent\n2. Pregnant Women\n3. Certain clinical\u002Fsurgical\u002Fanatomical parameters, at the discretion of the PI.",{"count":149,"type":20},80,"10 Years","OBSERVATIONAL","Liver transplantation (LT) has become an accepted treatment for selected patients with unresectable liver metastases due to colorectal cancer (CRLM). The goal of this study is to look at and compare the clinical results of all the different approved methods (living vs. Deceased, whole organ vs. Split, one staged vs. Two staged) used to perform a standard liver transplant procedure for recipients with CRLM. Investigators will look at things like different procedure results, recovery in the hospital, and survival rates one year after the transplant. Investigators will also take blood samples from participants to be used in future research. All the transplant methods the investigators are comparing are standard practices approved by the United Network of Organ Sharing (UNOS).",[28,154,155],"Colorectal Cancer Metastatic","Colon Cancer Liver Metastases",[27,154,157],"Colorectal Cancer","2026-02-06",{"date":160,"type":40},"2026-02-10",{"date":162,"type":40},"2025-08-27",{"date":164,"type":20},"2035-01-01",{"name":166,"class":47},"Northwestern University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":48},"100613381","phase-4-fibrinogen-in-liver-transplant-100613381","NCT07265843","Fibrinogen in Liver Transplant","Fibrinogen in Liver Transplant Subjects (FITS)","Inclusion Criteria:\n\n* 18 years of age or older\n* Scheduled to undergo cadaveric liver transplant\n* Meets at least one of the following criteria:\n* Baseline fibrinogen \\\u003C200 mg\u002FdL or clinically significant visoelastic testing,\n* Alcoholic cirrhosis,\n* Nonalcoholic Steatohepatitis (NASH),\n* HCV infection\n\nExclusion Criteria:\n\n* Living related donor transplant,\n* Known prothrombotic disorder,\n* Patient objection to blood transfusion,\n* Known severe allergic reaction to plasma-based products,\n* IgA deficiency with known hypersensitivity reaction to plasma,\n* Hepatocellular\u002Fcholangio carcinoma,\n* Primary biliary fibrosis",{"count":175,"type":20},60,[177],"PHASE4","The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.",[28],[181],"Cryoprecipitate","2025-12-01",{"date":184,"type":40},"2025-12-05",{"date":186,"type":20},"2026-01-01",{"date":188,"type":20},"2028-03-01",{"name":190,"class":47},"Trauma Hemostatis and Oxygenation Research (THOR) Network",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100571812","phase-1-using-radiotherapy-and-immunotherapy-to-treat-advanced-liver-cancer-before-transplant-100571812","NCT06725121","Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant","Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial","MacroTrans","Inclusion Criteria:\n\n* Age 18-70\n* Weight \\> 30 kg\n* Child Pugh Turcotte score A5 to B7\n* Macrovascular invasion (Vp1-3)\n* Total tumour volume \\\u003C 350 cm3\n* Alpha Fetoprotein \\\u003C 5000 ng\u002FmL\n* No extrahepatic disease\n* No other contraindications to undergo a LT\n* Eastern Cooperative Oncology Group (ECOG) score 0-1\n* Capable to provide inform consent\n* Radiological and histological confirmation of hepatocellular carcinoma\n\nExclusion Criteria:\n\n* Poorly differentiated HCC\n* Prior therapy for hepatocellular carcinoma other than liver resection or ablation\n* Portal vein tumor thrombus extending beyond main portal vein\n* Obesity class III (BMI ≥ 40 kg\u002Fm2)\n* Contraindications for radiotherapy (Y90 or SBRT) or AtezoBev","70 Years",{"count":201,"type":20},48,[203,204],"PHASE1","PHASE2","The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.\n\nThe main questions it aims to answer are:\n\n* How many patients will achieve transplant with this treatment strategy?\n* What will the 5-year survival and recurrence-free survival rates be for these patients?\n\nParticipants will:\n\n* Undergo a biopsy of the tumor.\n* Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months.\n* Be referred for a liver transplant and undergo the procedure if deemed eligible and safe.\n* If applicable, be followed for five years post-transplant with regular data collection.",[207,208,28,209],"Hepatocellular Carcinoma (HCC)","Macrovascular Invasion","Downstaging",[211,212,213,214,215,216,217,218,219,220,221,26],"SBRT","Y-90","Yittrium-90","Atezolizumab","Bevacizumab","Advanced liver cancer","Radiotherapy","Immunotherapy","Liver cancer","Stereotactic body radiotherapy","Transplant","2024-12-11",{"date":224,"type":40},"2024-12-16",{"date":226,"type":20},"2024-12",{"date":228,"type":20},"2034-06",{"name":230,"class":47},"University Health Network, Toronto",2]